Second Sight Medical Products (EYES) Receives Coverage Optimism Rating of 0.15

News stories about Second Sight Medical Products (NASDAQ:EYES) have been trending somewhat positive on Tuesday, Accern reports. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Second Sight Medical Products earned a news impact score of 0.15 on Accern’s scale. Accern also assigned headlines about the medical device company an impact score of 43.7630125000645 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Shares of Second Sight Medical Products (NASDAQ:EYES) opened at $1.92 on Tuesday. The firm has a market capitalization of $109.07, a price-to-earnings ratio of -2.87 and a beta of 3.71. Second Sight Medical Products has a twelve month low of $0.90 and a twelve month high of $2.83.

Second Sight Medical Products (NASDAQ:EYES) last posted its earnings results on Thursday, November 2nd. The medical device company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02. The company had revenue of $1.61 million during the quarter, compared to analyst estimates of $1.54 million. Second Sight Medical Products had a negative return on equity of 184.87% and a negative net margin of 565.12%. analysts forecast that Second Sight Medical Products will post -0.55 earnings per share for the current fiscal year.

A number of analysts have weighed in on the company. Zacks Investment Research upgraded Second Sight Medical Products from a “sell” rating to a “hold” rating in a report on Monday. HC Wainwright set a $5.00 target price on Second Sight Medical Products and gave the stock a “buy” rating in a report on Tuesday, October 17th.

COPYRIGHT VIOLATION NOTICE: This piece was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at

Second Sight Medical Products Company Profile

Second Sight Medical Products, Inc is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight.

Insider Buying and Selling by Quarter for Second Sight Medical Products (NASDAQ:EYES)

What are top analysts saying about Second Sight Medical Products? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Second Sight Medical Products and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit